公开(公告)号：US12097307B2

公开(公告)日：2024-09-24

申请号：US17377124

申请日：2021-07-15

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo Vegas ,  Joshua C. Doloff ,  Omid Veiseh ,  Minglin Ma ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61K9/50 ,  A61K9/00 ,  A61K9/48 ,  A61K35/39 ,  A61K47/36 ,  A61L29/08 ,  A61L31/10 ,  A61L33/08 ,  C07D487/04 ,  C08B37/00 ,  C12N5/00 ,  C12N5/071

CPC classification number: A61L29/085 ,  A61K9/0024 ,  A61K9/4816 ,  A61K9/5036 ,  A61K35/39 ,  A61K47/36 ,  A61L31/10 ,  A61L33/08 ,  C07D487/04 ,  C08B37/0084 ,  C12N5/0012 ,  C12N5/0677

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

公开(公告)号：US20220031913A1

公开(公告)日：2022-02-03

申请号：US17377124

申请日：2021-07-15

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo Vegas ,  Joshua C. Doloff ,  Omid Veiseh ,  Minglin Ma ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61L29/08 ,  A61K47/36 ,  A61K9/48 ,  A61K35/39 ,  C08B37/00 ,  A61K9/00 ,  A61K9/50 ,  A61L31/10 ,  A61L33/08 ,  C07D487/04 ,  C12N5/00 ,  C12N5/071

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

公开(公告)号：US10786446B2

公开(公告)日：2020-09-29

申请号：US16200334

申请日：2018-11-26

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Minglin Ma ,  Daniel G. Anderson ,  Robert S. Langer ,  Omid Veiseh ,  Joshua Charles Doloff ,  Delai Chen ,  Christian J. Kastrup ,  Arturo Jose Vegas

IPC: A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/39 ,  A61K45/06 ,  B01J13/04 ,  A61K35/12

Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

公开(公告)号：US10730983B2

公开(公告)日：2020-08-04

申请号：US15621391

申请日：2017-06-13

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Omid Veiseh ,  Volkan Yesilyurt ,  Arturo Vegas ,  Joshua Doloff ,  Daniel G. Anderson ,  Robert S. Langer

IPC: C08F230/02 ,  A61L29/08 ,  A61L27/26 ,  A61L27/52 ,  A61L27/34 ,  A61L27/38 ,  A61L27/54 ,  A61K35/12 ,  A61K9/50 ,  A61L29/04 ,  A61L31/10 ,  A61L31/04 ,  A61L27/56 ,  A61L29/16 ,  A61L31/16 ,  C08F220/38 ,  C08F30/02 ,  C08F20/38 ,  A61B5/145

Abstract: Zwitterionic polymers or biocompatible polymers with improved properties for cell encapsulation, coating of devices, or a combination thereof are described. The biocompatible polymer contains a zwitterionic monomer, a monomer with a reactive side chain, and optionally another hydrophobic monomer or a neutral hydrophilic monomer. The zwitterionic polymers are cross-linked with a cross-linker via covalent bond to form a zwitterionic hydrogel in the presence of cells. Also provided, are methods of making and using the zwitterionic polymers.

公开(公告)号：US10683379B2

公开(公告)日：2020-06-16

申请号：US15078685

申请日：2016-03-23

Applicant: Massachusetts Institute of Technology

Inventor： Daniel Griffith Anderson ,  Eric Andrew Appel ,  Yizhou Dong ,  Robert S. Langer ,  Benjamin C. Tang ,  Omid Veiseh ,  Weiheng Wang ,  Matthew J. Webber ,  Kun Xue

IPC: C08F8/12 ,  C08F8/28 ,  A61K47/32 ,  C08F120/56 ,  C08F120/60 ,  C08F130/06 ,  C08F220/56 ,  C08F220/60 ,  C08F230/06

Abstract: Described herein are polymers, polymeric gels, or a composition thereof, for drug delivery. The polymers, which include boronic-acid containing moieties (e.g., and polyol-containing moieties (e.g., are prepared by free-radical polymerization and can self-assemble into polymeric gels such as hydrogels. Also provided are methods or preparing the polymers, kits involving the polymers and/or polymeric gels or a composition thereof, for use as materials or delivery applications of an agent to a subject.

公开(公告)号：US10426735B2

公开(公告)日：2019-10-01

申请号：US14817084

申请日：2015-08-03

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo J. Vegas ,  Joshua C. Doloff ,  Omid Veiseh ,  Minglin Ma ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61K35/39 ,  A61K9/50 ,  C08B37/00 ,  C12N5/00 ,  C12N5/071 ,  A61K9/00 ,  A61L29/08 ,  A61L31/10 ,  A61L33/08

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

公开(公告)号：US20190134277A1

公开(公告)日：2019-05-09

申请号：US16182307

申请日：2018-11-06

Applicant: Massachusetts Institute of Technology ,  Seattle Children's Hospital d/b/a Seattle Children's Research Institute

Inventor： Omid Veiseh ,  Robert S. Langer ,  Daniel G. Anderson ,  William Shain ,  Brian W. Hanak ,  Samuel R. Browd ,  Robert F. Hevner

IPC: A61L29/08 ,  A61L29/16

Abstract: Neurological implants whose surfaces have been chemically and covalently modified to impart beneficial properties to the neurological implants are described. The neurological implants possess improved biocompatibility compared to a corresponding neurological implant that lacks the chemical modification. Following implantation in a subject, the surface-modified neurological implants induce a lower-foreign body response, compared to a corresponding unmodified product.

公开(公告)号：US20180360765A1

公开(公告)日：2018-12-20

申请号：US16108465

申请日：2018-08-22

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo J. Vegas ,  Joshua C. Doloff ,  Omid Veiseh ,  Minglin Ma ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61K9/50 ,  C08B37/00 ,  A61K35/39 ,  C12N5/00 ,  A61L29/08 ,  C12N5/071 ,  A61L33/08 ,  A61K9/00 ,  A61L31/10 ,  C08L5/04

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

公开(公告)号：US12186453B2

公开(公告)日：2025-01-07

申请号：US15341118

申请日：2016-11-02

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo J. Vegas ,  Joshua C. Doloff ,  Omid Veiseh ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61L27/38 ,  A61K9/00 ,  A61K35/36 ,  A61K38/02 ,  A61L27/04 ,  A61L27/10 ,  A61L27/16 ,  A61L27/18 ,  A61L27/20 ,  A61L27/34 ,  A61L27/54 ,  A61L27/56 ,  A61L29/14 ,  C08J7/12 ,  A61K35/12 ,  A61K35/39

Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.

公开(公告)号：US11318231B2

公开(公告)日：2022-05-03

申请号：US16182307

申请日：2018-11-06

Applicant: Massachusetts Institute of Technology ,  Seattle Children's Hospital

Inventor： Omid Veiseh ,  Robert S. Langer ,  Daniel G. Anderson ,  William Shain ,  Brian W. Hanak ,  Samuel R. Browd ,  Robert F. Hevner

IPC: A61K31/192 ,  A61L29/08 ,  A61L29/16 ,  G01N33/68 ,  A61L31/06 ,  A61L27/34 ,  A61L29/06 ,  A61L31/10 ,  A61L31/16 ,  A61L27/18 ,  A61L27/54 ,  A61M27/00

Abstract: Neurological implants whose surfaces have been chemically and covalently modified to impart beneficial properties to the neurological implants are described. The neurological implants possess improved biocompatibility compared to a corresponding neurological implant that lacks the chemical modification. Following implantation in a subject, the surface-modified neurological implants induce a lower-foreign body response, compared to a corresponding unmodified product.